EGFR and non-small cell lung carcinoma: Schematic showing the design of this first‐in‐human multicenter, open‐label Phase 1 study of DS‐1205c in combination with gefitinib in subjects with metastatic or unresectable EGFR‐mutant NSCLC and disease progression during treatment with one or more EGFR‐TKIs (gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib).